NXTC NextCure Inc

Price (delayed)

$4.24

Market cap

$15.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.19

Enterprise value

$4.03M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune ...

Highlights
NXTC's debt is down by 21% year-on-year and by 6% since the previous quarter
The EPS has grown by 19% YoY and by 13% from the previous quarter
The quick ratio has plunged by 56% YoY but it has grown by 9% from the previous quarter
NXTC's net income is down by 10% year-on-year but it is up by 2.1% since the previous quarter
NextCure's equity has shrunk by 52% YoY and by 24% QoQ

Key stats

What are the main financial stats of NXTC

NXTC stock price

How has the NextCure stock price performed over time
Intraday
1.44%
1 week
-29.22%
1 month
139.55%
1 year
-19.39%
YTD
-70.12%
QTD
165%

Financial performance

How have NextCure's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.1M
Net income
-$54.66M
Gross margin
N/A
Net margin
N/A
NXTC's net income is down by 10% year-on-year but it is up by 2.1% since the previous quarter
NextCure's operating income has decreased by 6% YoY but it has increased by 2.6% from the previous quarter

Price vs fundamentals

How does NXTC's price correlate with its fundamentals

Growth

What is NextCure's growth rate over time

Valuation

What is NextCure stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 19% YoY and by 13% from the previous quarter
NextCure's equity has shrunk by 52% YoY and by 24% QoQ
The P/B is 37% lower than the last 4 quarters average of 0.9 but 14% higher than the 5-year quarterly average of 0.5

Efficiency

How efficient is NextCure business performance
NXTC's return on equity has dropped by 171% year-on-year and by 23% since the previous quarter
NextCure's return on invested capital has shrunk by 153% YoY and by 22% QoQ
NXTC's ROA has shrunk by 114% YoY and by 14% QoQ

Dividends

What is NXTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NXTC.

Financial health

How did NextCure financials performed over time
The quick ratio has plunged by 56% YoY but it has grown by 9% from the previous quarter
NXTC's current ratio has dropped by 55% year-on-year but it is up by 11% since the previous quarter
NXTC's debt is 85% smaller than its equity
The debt to equity has surged by 67% year-on-year and by 25% since the previous quarter
NextCure's equity has shrunk by 52% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.